[CIS PIDD] [cis-pidd] PSTPIP1 deletion

[Zastawny, Edward M]

If pt shows a response to Anakinra (IL-1 receptor antagonist) and longer term treatment is indicated, rilonacept [Arcalyst (R)] or canakinumab [Ilaris (R)] may be more convenient options. Rilonacept (subQ) is an IL-1 'trap' and canakinumab (subQ) is a mAb vs IL-1. Rilonacept is dosed weekly and canakinumab is dosed every 4-8 weeks.

-----Original Message-----
From: Verbsky, James [mailto:jverbsky at mcw.edu] 
Sent: Wednesday, January 07, 2015 12:24 AM
To: CIS-PIDD
Subject: Re: [cis-pidd] PSTPIP1 deletion

Dylan

Sounds fairly convincing.  Was the mutation a homozygous deletion?

Anakinra might be a good choice as this has been reported to be effective.


Best

James

James Verbsky MD/PhD
Associate Professor of Pediatrics
Departments of Pediatrics and Microbiology Medical Director, Clinical Immunology Research Laboratory Medical Director, Clinical and Translational Research Medical College of Wisconsin/Children's Hospital of Wisconsin Milwaukee, WI  53226

From: Dylan Mordaunt <d.a.mordaunt at gmail.com<mailto:d.a.mordaunt at gmail.com>>
Reply-To: CIS-PIDD <cis-pidd at lists.clinimmsoc.org<mailto:cis-pidd at lists.clinimmsoc.org>>
Date: Tuesday, January 6, 2015 at 9:32 PM
To: CIS-PIDD <cis-pidd at lists.clinimmsoc.org<mailto:cis-pidd at lists.clinimmsoc.org>>
Subject: [cis-pidd] PSTPIP1 deletion

Hi all,

We are seeing a 23 mo male with episodic fevers since soon after birth, failure to thrive, recurrent face and skin lesions which have been considered to be boils and recurrent giardiasis (he lives in an extremely remote area where this is endemic).

Sequencing of the InFevers genes showed no mutations, however a ~5 kb deletion of PSTPIP1 involving the SH3 domain was detected on an exon array. There do not appear to have been either nonsense mutations nor deletions of PSTPIP1 reported, though this seems very likely to be pathogenic.

I'm wondering whether anyone in the list has a patient with a deletion and whether they could provide insight into the evolution of the disorder and response to therapy?

Kind regards,

Dylan


Dylan Mordaunt
Clinical and Metabolic Genetics Fellow
South Australian Clinical Genetics Service
Mobile: + 61 468 516 283
Email: d.a.mordaunt at gmail.com<mailto:d.a.mordaunt at gmail.com>

---

The CIS-PIDD listserv is supported by:

[http://www.clinimmsoc.org/UserFiles/image/cis-pidd-list-logo_v1.jpg]
The science & practice of human immunology

P: +1.414.224.8095
E: info at clinimmsoc.org<mailto:info at clinimmsoc.org>

Not a member of CIS? Please visit www.clinimmsoc.org<https://cis.execinc.com/edibo/Signup> to join!

You are currently subscribed to cis-pidd as: jverbsky at mcw.edu<mailto:jverbsky at mcw.edu>.
To unsubscribe click here: http://lm.clinimmsoc.org/u?id=183824783.922c198296ffdc754aad9421f3d685e1&n=T&l=cis-pidd&o=45917696

---
The CIS-PIDD listserv is supported by the Clinical Immunology Society The science & practice of human immunology

P: +1.414.224.8095
E: info at clinimmsoc.org

Not a member of CIS? Please visit www.clinimmsoc.org to join!

You are currently subscribed to cis-pidd as: edward_zastawny at baxter.com.
To unsubscribe click here: http://lm.clinimmsoc.org/u?id=187964069.759125737dc03382513962cfa4dda2d3&n=T&l=cis-pidd&o=45918245
or send a blank email to leave-45918245-187964069.759125737dc03382513962cfa4dda2d3 at lists.clinimmsoc.org
The information transmitted is intended only for the person(s) or entity to which it is addressed and may contain confidential and/or legally privileged material. Delivery of this message to any person other than the intended recipient(s) is not intended in any way to waive privilege or confidentiality. Any review, retransmission, dissemination or other use of, or taking of any action in reliance upon, this information by entities other than the intended recipient is prohibited. If you receive this in error, please contact the sender and delete the material from any computer.

For Translation:

http://www.baxter.com/email_disclaimer


---
The CIS-PIDD listserv is supported by the Clinical Immunology Society
The science & practice of human immunology

P: +1.414.224.8095
E: info at clinimmsoc.org

Not a member of CIS? Please visit www.clinimmsoc.org to join!

You are currently subscribed to cis-pidd as: pagid at list.clinimmsoc.org.
To unsubscribe click here: http://lm.clinimmsoc.org/u?id=183939985.3ea13d40a15475ac00ebbd9cd8a37d6d&n=T&l=cis-pidd&o=45919627
or send a blank email to leave-45919627-183939985.3ea13d40a15475ac00ebbd9cd8a37d6d at lists.clinimmsoc.org